Home > Drugs A-Z > Koate

Koate (KEDRION BIOPHARMA, INC)

Available Formats

Dosage Form Package Information Links
KIT 1 KIT in 1 CARTON (76125-250-20) * 5 mL in 1 VIAL, GLASS * 5 mL in 1 VIAL, GLASS Label Information

Complete Koate Information

  • HIGHLIGHTS OF PRESCRIBING INFORMATION
    These highlights do not include all the information needed to use KOÄ€TE ® safely and effectively. See full prescribing information for KOÄ€TE.

    KOÄ€TE ®, Antihemophilic Factor (Human)
    Lyophilized Powder for Solution for Intravenous Injection
    Initial U.S. Approval: 1974

    RECENT MAJOR CHANGES

    Dosage and Administration (2.1) 12/2015
    Contraindications (4) 12/2015
    Warnings and Precautions, Neutralizing Antibodies (5.2) 12/2015

    INDICATIONS AND USAGE

    KOÄ€TE is a human plasma-derived  antihemophilic factor indicated for the control and prevention of bleeding episodes or in order to perform emergency and elective surgery in patients with hemophilia A (hereditary Factor VIII deficiency). (1)


    Limitation of Use

    KOÄ€TE is not indicated for the treatment of von Willebrand disease.

    DOSAGE AND ADMINISTRATION

    For intravenous use after reconstitution only.

        Each vial of KOÄ€TE contains the labeled amount of Factor VIII in international units (IU). (2)
        Required Dose (IU) = Body Weight (kg) x Desired Factor VIII Rise (IU/dL or % of normal) x 0.5
        Frequency of KOÄ€TE administration is determined by the type of bleeding episode and the recommendation of the treating physician.

    DOSAGE FORMS AND STRENGTHS

    KOÄ€TE is available as a lyophilized powder for reconstitution in single-use vials of 250, 500, and 1,000 international units of Factor VIII activity. (3)

    CONTRAINDICATIONS

    Do not use in patients who have known hypersensitivity reactions, including anaphylaxis, to KOÄ€TE or its components. (4)

    WARNINGS AND PRECAUTIONS

       Hypersensitivity reactions, including anaphylaxis, are  possible. Should symptoms occur, discontinue  KOÄ€TE and administer appropriate treatment. (5.1)
       Development of neutralizing antibodies (inhibitors)  may occur. If expected plasma Factor VIII activity levels are not attained, or if bleeding is not controlled with an appropriate dose, perform an assay that measures Factor VIII inhibitor concentration. (5.2)
       Monitor for intravascular hemolysis and decreasing hematocrit values in patients with A, B or AB blood groups who are receiving large or frequent doses. (5.3)
       KOÄ€TE is made from human blood and therefore carries a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. (5.4)

    ADVERSE REACTIONS

    The most common adverse drug reactions (frequency ≥ 5% of subjects) observed in the clinical trial were nervousness, headache, abdominal pain, nausea, paresthesia and blurred vision. (6)

    To report SUSPECTED ADVERSE REACTIONS, contact Grifols Therapeutics Inc. at 1-800-520-2807 or FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch.

    USE IN SPECIFIC POPULATIONS

    Pediatric: clearance of Factor VIII (based on per kilogram body weight) is higher in children.  Higher or more frequent dosing may be needed. (8.4)

    See 17 for PATIENT COUNSELING INFORMATION.

    Revised: 2/2016


  • FULL PRESCRIBING INFORMATION: CONTENTS*
  • 1 Indications and Usage

    KOÄ€TE® is a human plasma-derived antihemophilic factor indicated for the control and prevention of bleeding episodes or in order to perform emergency and elective surgery in patients with hemophilia A (hereditary Factor VIII deficiency).

    Limitation of Use

    KOÄ€TE is not indicated for the treatment of von Willebrand disease.


  • 2 Dosage and Administration

    For intravenous use after reconstitution only.

    2.1 Dose
    • Dose and duration of treatment depend on the severity of the Factor VIII deficiency, location and extent of bleeding, and the patient’s clinical condition.
    • Each vial of KOÄ€TE is labeled with the actual Factor VIII potency in international units (IU). Calculation of the required dose of Factor VIII is based on the empirical finding that one IU of Factor VIII per kg body weight raises the plasma Factor VIII activity by approximately 2% of normal activity or 2 IU/dL.
    • The required dose can be determined using the following formula:

      Dose (IU) = Body Weight (kg) x Desired Factor VIII Rise (% normal or IU/dL) x 0.5

    • Estimate the expected in vivo peak increase in Factor VIII level, expressed as IU/dL (or % normal), using the following formula:

                    Estimated Increment of Factor VIII
      (% normal or IU/dL) = [Total Dose (IU)/Body Weight (kg)] x 2

    • Patients may vary in their pharmacokinetic (e.g., half-life, in vivo recovery) and clinical responses. Base the dose and frequency on the individual clinical response.

    Control and Prevention of Bleeding Episodes

    A guide for dosing KOÄ€TE for the control and prevention of bleeding episodes (1,2) is provided in Table 1. Consideration should be given to maintaining a Factor VIII activity at or above the target range.

    Table 1: Dosage Guidelines for Patients with Hemophilia A
    Type of Bleeding Factor VIII:C
    Level Required

    (% of normal)
    Doses
    (IU/kg)
    Frequency of Doses 
      (hours)
    Duration of Therapy
    (days)
    Minor
    Large bruises

    Significant cuts or scrapes

    Uncomplicated joint hemorrhage
    30 15 12 


    (twice daily)
    Until hemorrhage stops and healing has been achieved (1–2 days).
    Moderate
    Nose, mouth and gum bleeds

    Dental extractions

    Hematuria
    50 25 12

    (twice daily)
    Until healing has been achieved (2–7 days, on average).
    Major
    Joint hemorrhage

    Muscle hemorrhage

    Major trauma

    Hematuria

    Intracranial and intraperitoneal bleeding
    80-100 Initial: 40-50


       Maintenance:
    25
    12


    (twice daily)
    For at least 3–5 days  


    Until healing has been achieved for up to 10 days.  Intracranial hemorrhage may require prophylaxis therapy for up to 6 months.
    Surgery Prior to surgery:
    80-100  

    After surgery:
    60-100
    40-50


    30-50
    Once    


    12
    (twice daily)
    Prior to surgery    


    For the next 7–10 days, or until healing has been achieved.

    2.2 Preparation and Reconstitution
    1. Use aseptic technique (clean and sanitized) and a flat work surface during the reconstitution procedure.
    2. Bring the vials of KOÄ€TE and the diluent (Sterile Water for Injection) to room temperature before use.
    3. Remove the shrink band from the KOÄ€TE vial. Do not use KOÄ€TE if the shrink band is absent or shows signs of tampering, and notify Grifols Therapeutics Inc. immediately.
    4. Remove the plastic cap from the KOÄ€TE vial (Fig. A) and clean the  top of the stopper with an alcohol swab. Allow the stopper to dry.
    5. Repeat this step with the vial of sterile water.
    6. Carefully remove the plastic sheath from the short end of the transfer needle and insert the exposed needle into the diluent vial to the hub (Fig. B)
    7. Place the KOÄ€TE vial upright on a flat surface. Remove the sheath from the other end of the transfer needle.
    8. While holding the KOÄ€TE vial securely on a flat surface insert the needle into the vial  at a 45° angle to minimize foaming (Fig. C). The vacuum will draw the diluent into the concentrate vial. If vacuum is lost, use a sterile syringe and needle to remove the sterile water from the diluent vial and inject it into the KOÄ€TE, directing the stream of fluid against the wall of the vial.
    9. Remove the diluent vial and transfer needle (Fig. D).
    10. Agitate vigorously for 10-15 seconds, (Fig. E1) then swirl continuously until completely dissolved (Fig. E2). Avoid excessive foaming. The reconstituted solution should be clear to opalescent. Do not use if particulate matter and discoloration  is observed.
    11. Clean the top of the vial of reconstituted KOÄ€TE with alcohol swab and let surface dry.
    12. Attach the filter needle (from the package) to a sterile syringe. Withdraw the KOÄ€TE solution into the syringe through the filter needle (Fig. F).
    13. Remove the filter needle from the syringe and discard the filter needle into a puncture proof container. Use KOÄ€TE within 3 hours after reconstitution. Do not refrigerate after reconstitution.
    Figures A-F

    2.3 Administration

    For intravenous administration only

    • If the dose requires more than one vial of KOÄ€TE:
      • Reconstitute each vial using a new transfer needle.
      • Draw up all the solution into a single syringe.
    • Visually inspect the final solution for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use if particulate matter or discoloration is observed.
    • Attach the syringe to the connector end of an infusion set.
    • Administer intravenously. The rate of administration should be determined by the patient’s comfort level, and no faster than 10 mL per minute.

  • 3 DOSAGE FORMS AND STRENGTHS

    KOÄ€TE is available as a lyophilized powder for reconstitution in single-use vials of 250, 500 and 1,000 IU of Factor VIII activity. The actual Factor VIII potency is labeled on each KOÄ€TE vial.


  • 4 CONTRAINDICATIONS

    KOÄ€TE is contraindicated in patients who have had hypersensitivity reactions, including anaphylaxis, to KOÄ€TE or its components.[see Description (11)]


  • 5 WARNINGS AND PRECAUTIONS

    5.1 Hypersensitivity Reactions

    Hypersensitivity reactions, including anaphylaxis, are possible. Early signs of hypersensitivity reactions, which can progress to anaphylaxis, may include angioedema, chest tightness, hypotension, rash, nausea, vomiting, paresthesia, restlessness, wheezing and dyspnea.  If hypersensitivity symptoms occur, discontinue use of the product immediately and administer appropriate emergency treatment.

    5.2 Neutralizing Antibodies

    The formation of neutralizing antibodies (inhibitors) to Factor VIII may occur. Monitor all patients for the development of Factor VIII inhibitors by appropriate clinical observations and laboratory tests. If expected plasma Factor VIII activity levels are not attained, or if bleeding is not controlled with an appropriate dose, perform an assay that measures Factor VIII inhibitor concentration. [see Warnings and Precautions (5.5)]

    5.3 Intravascular Hemolysis

    KOÄ€TE contains blood group isoagglutinins which are not clinically significant when small doses are used to treat minor bleeding episodes. However, when large and/or frequent doses of KOÄ€TE are given to patients with blood groups A, B, or AB, acute hemolytic anemia may occur, resulting in increased bleeding tendency or hyperfibrinogenemia. Monitor these patients for signs of  intravascular hemolysis and falling hematocrit. [see Warnings and Precautions (5.5)] Should this condition occur, leading to progressive hemolytic anemia, discontinue KOÄ€TE and consider administering serologically compatible Type O red blood cells and providing alternative therapy.

    5.4 Transmissible Infectious Agents

    Because KOÄ€TE is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. There is also the possibility that unknown infectious agents may be present in the product. The risk that the product will transmit viruses has been reduced by screening plasma donors for prior exposure to certain viruses, by testing for the presence of certain current virus infections, and by inactivating and removing certain viruses during manufacture. Despite these measures, this product may still potentially transmit diseases.

    Report all infections suspected by a physician possibly to have been transmitted by this product to Grifols Therapeutics Inc. at 1-800-520-2807. 

    5.5 Monitoring: Laboratory Tests
    • Monitor plasma Factor VIII activity levels by performing a validated test (e.g., one-stage clotting assay) to confirm that adequate Factor VIII levels have been achieved and maintained. [see Dosage ad Administration (2.1)]
    • Monitor for the development of Factor VIII inhibitors. Perform a Bethesda inhibitor assay if expected Factor VIII plasma levels are not attained, or if bleeding is not controlled with the expected dose of KOÄ€TE. Use Bethesda Units (BU) to report inhibitor levels.
    • Monitor for intravascular hemolysis and decreasing hematocrit values in patients with A, B or AB blood groups who are receiving large or frequent doses of KOÄ€TE.

  • 6 ADVERSE REACTIONS

    The most common adverse drug reactions (frequency ≥ 5 % of subjects) observed in the clinical trial were nervousness, headache, abdominal pain, nausea, paresthesia and blurred vision.

    6.1 Clinical Trials Experience

    Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed cannot be directly compared to rates in other clinical trials and may not reflect the rates observed in practice.

    The safety assessment of KOÄ€TE is based on data from a 2-stage, safety, pharmacokinetic (PK) and efficacy clinical trial in which twenty subjects with severe hemophilia A (<1% endogenous Factor VIII activity) were evaluable for safety. Nineteen subjects were enrolled in Stage I of the trial, including 15 Caucasian, 3 Hispanic, and 1 Black subjects. The mean age was 29 years (range: 13.9 – 46.4 years). Nineteen subjects, including the 18 subjects who completed Stage I, and one new subject were enrolled in Stage II. The mean age was 30 years (range: 13.9 – 46.4). The subjects received a total of 1053 infusions. Ten adverse reactions related to 7 infusions were reported in 4 subjects.  These were: nervousness (2 subjects [10%]), headache (1 subject [5%]), abdominal pain (1 subject [5%]), nausea (1 subject [5%]), paresthesia (1 subject [5%]), and blurred vision (1 subject [5%]).

    Immunogenicity

    Subjects were monitored for neutralizing antibodies (inhibitors) to Factor VIII by the Bethesda assay at baseline and at 8, 17 and 26 weeks. No evidence of inhibitor formation was observed in the clinical trial.

    The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, it may be misleading to compare the incidence of antibodies to KOÄ€TE in the study described above with the incidence of antibodies in other studies or to other products.

    6.2 Postmarketing Experience

    Because postmarketing reporting of adverse reactions is voluntary and from a population of uncertain size, it is not always possible to reliably estimate the frequency of these reactions or establish a causal relationship to product exposure.

    • Blood and Lymphatic System Disorders: Factor VIII inhibition, hemolytic anemia
    • Immune System Disorders: Hypersensitivity including anaphylaxis, rash, pruritus
    • Injury, Poisoning and Procedural Complications: Post-procedural hemorrhage
    • Nervous System Disorders: Generalized clonic-tonic seizure

  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    Risk Summary

    There are no data with KOÄ€TE use in pregnant women to inform on drug-associated risk. Animal reproduction studies have not been conducted using KOÄ€TE. It is not known whether KOÄ€TE can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. KOÄ€TE should be given to a pregnant woman only if clearly needed. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

    8.2 Lactation

    Risk Summary

    There is no information regarding the presence of KOĀTE in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for KOĀTE and any potential adverse effects on the breast-fed infant from KOĀTE or from the underlying maternal condition.

    8.4 Pediatric Use

    Safety and efficacy studies have been performed in 20 previously treated pediatric patients aged 2.5 to 16 years. Subjects received 208 infusions of KOÄ€TE for treatment or control of bleeding episodes, including perioperative management, and routine prophylaxis. Children have shorter half-life and lower recovery of Factor VIII than adults. Because clearance of Factor VIII (based on per kilogram body weight) is higher in children, higher or more frequent dosing may be needed.

    8.5 Geriatric Use

    Clinical studies of KOÄ€TE did not include any subjects aged 65 and over to determine whether they respond differently from younger subjects. Individualize dose selection for geriatric patients.


  • 11 DESCRIPTION

    KOÄ€TE, Antihemophilic Factor (Human), is a sterile, stable, dried concentrate of human antihemophilic factor  in lyophilized powder form for reconstitution for intravenous injection.  The product is supplied in single-use vials containing nominally 250, 500, or 1,000 international units (IU or units). Each vial of KOÄ€TE is labeled with the actual amount of Factor VIII expressed in IU. One IU is defined by the current World Health Organization International Standard for Factor VIII concentrate, which can be traced to the level of Factor VIII found in 1 mL of fresh pooled human plasma. The final product when reconstituted as directed contains not more than (NMT) 1500 μg/mL polyethylene glycol (PEG), NMT 0.05 M glycine, NMT 25 μg/mL polysorbate 80, NMT 5 μg/g tri-n-butyl phosphate (TNBP), NMT 3 mM calcium, NMT 1 μg/mL aluminum, NMT 0.06 M histidine, and NMT 10 mg/mL human albumin.

    KOÄ€TE is purified from the cold insoluble fraction of pooled human plasma; the manufacturing process includes solvent/detergent (TNBP and polysorbate 80) treatment and heat treatment of the lyophilized final container. A gel permeation chromatography step serves the dual purpose of reducing the amount of TNBP and polysorbate 80 as well as increasing the purity of the Factor VIII in KOÄ€TE to 300 to 1,000 times over whole plasma. When reconstituted as directed, KOÄ€TE contains approximately 50 to 150 times as much Factor VIII as an equal volume of fresh plasma. The specific activity after addition of human albumin is in the range of 9 to 22 units/mg protein. KOÄ€TE also contains naturally occurring von Willebrand factor, which is co-purified as part of the manufacturing process.

    The KOÄ€TE manufacturing process includes two dedicated steps with virus inactivation capacity. The solvent/detergent treatment step has the capacity to inactivate enveloped viruses (such as HIV, HCV, HBV, and WNV). Heat treatment at 80ºC for 72 hours has the capacity to inactivate enveloped viruses (such as HIV and HCV) as well as non‑enveloped viruses (such as HAV and B19V). The polyethylene glycol (PEG) precipitation/depth filtration step has the capacity to remove both enveloped and non‑enveloped viruses. The accumulated virus reduction factors for KOÄ€TE manufacturing process are presented in Table 2.

    Table 2: Virus Clearance Capacity (Log10) for the Antihemophilic Factor (Human) Manufacturing Process
    * WNV inactivation was evaluated only for the solvent/detergent treatment step
     

    Enveloped Viruses

    Non-enveloped Viruses

    HIV-1

    BVDV

    PRV

    VSV

    WNV

    Reo3

    HAV

    PPV

    Model for

    HIV-1/2

    HCV

    Large enveloped DNA viruses (e.g., herpes virus)

    Enveloped RNA viruses

    WNV

    Non-enveloped viruses

    HAV

    B19V

    Global Reduction Factor

    ≥ 12.0

    ≥ 11.5

    ≥ 10.8

    ≥ 10.9

    ≥ 5.9*

    ≥ 9.9

    ≥ 5.5

    4.8

    Additionally, the manufacturing process was investigated for its capacity to decrease the infectivity of an experimental agent of transmissible spongiform encephalopathy (TSE), considered a model for the variant Creutzfeldt-Jakob disease (vCJD) and Creutzfeldt-Jakob disease (CJD) agents. The manufacturing process has been shown to decrease TSE infectivity of that experimental model agent (a total of 5.1 log10 reduction), providing reasonable assurance that low levels of vCJD/CJD agent infectivity, if present in the starting material, would be removed.


  • 12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    KOÄ€TE temporarily replaces the missing clotting Factor VIII that is needed for effective hemostasis.

    12.2 Pharmacodynamics

    Hemophilia A is a bleeding disorder characterized by a deficiency of functional coagulation Factor VIII, resulting in a prolonged plasma clotting time as measured by the activated partial thromboplastin time (aPTT) assay. Treatment with KOÄ€TE normalizes the aPTT over the effective dosing period.

    12.3 Pharmacokinetics

    The pharmacokinetics (PK) of KOÄ€TE were evaluated in a prospective, two-stage clinical trial of 20 previously treated patients (PTPs) with severe hemophilia A. In Stage I, the PK parameters for 19 subjects were based on plasma Factor VIII activity after a single intravenous infusion of 50 IU/kg of KOÄ€TE. Bioequivalence of the dry heat-treated KOÄ€TE to the unheated KOÄ€TE was demonstrated by comparison of Cmax and the area under the curve, AUC0-48 (Table 3). The incremental in vivo recovery ten minutes after infusion of dry heat-treated KOÄ€TE was 1.90% unit/kg (unheated KOÄ€TE was 1.82% units/kg). Mean biologic half-life was 16.1 hours.

    In Stage II of the study, participants received KOÄ€TE treatments for six months on home therapy with a median of 52 days (range 23 to 94 days). At the end of 6 months, the mean AUC0-48 was 1471 ± 237 unit*hour/100 mL, the Cmax was 99 ± 13 unit/100 mL, and the t1/2was 16 ± 3.9 hours.

    Table 3: PK Parameters of KOÄ€TE (Stage I of Crossover Trial)
    Parameter KOÄ€TE
    Dry Heat-treated

    (mean ± SD)
    KOÄ€TE
    Unheated
    (mean ± SD)
      AUC0-48(IU hr/mL)) 1432 ±288 1477 ± 343
      Cmax(IU/mL)  103 ± 19 99 ± 20
      Tmax(hr) 0.41 ± 0.26 0.43 ± 0.44
    Half life (hr) 16.1 ± 3.2 16.1 ± 5.1

  • 14 CLINICAL STUDIES

    The efficacy of KOÄ€TE for the treatment of bleeding episodes was demonstrated in a 2-stage, safety, PK and efficacy clinical trial. Stage I was a randomized, single-blind, single-dose, crossover, and PK study comparing heat-treated KOÄ€TE with unheated KOÄ€TE. Nineteen subjects were randomized and received a single dose of 50 IU/kg of either heated KOÄ€TE or unheated KOÄ€TE for PK assessment.  Stage II was a 6 month open-label safety study conducted at two hemophilia centers. Nineteen subjects received KOÄ€TE, including for on-demand treatment and control of bleeding episodes. The study populations included 15 Caucasians, 3 Hispanic, and 1 Black subject. A total of 306 bleeding episodes were treated, of which 82% were treated with a single infusion of Factor VIII.


  • 15 REFERENCES

    1. Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia. Haemophilia 2013;19(1):e1-47.

    2. Abildgaard CF. Current concepts in the management of hemophilia. Semin Hematol 1975;12(3):223-32.

  • 16 HOW SUPPLIED/STORAGE AND HANDLING

    How Supplied

    KOÄ€TE is supplied in single-use vials containing 250, 500 or 1,000 IU of Factor VIII activity, packaged with 5 mL or 10 mL of Sterile Water for Injection, one sterile double-ended transfer needle, one sterile filter needle, and one sterile administration set. The actual amount of KOÄ€TE in IU is stated on each carton and vial label.

    Components used in the packaging of KOÄ€TE are not made with natural rubber latex.

    Strength

    NDC Number
    Carton (Kit)

    250 IU

    76125-250-20 or 76125-253-25

    500 IU

    76125-667-30 or 76125-662-50

    1,000 IU

    76125-672-50 or 76125-674-10

    Storage and Handling

    • Store KOÄ€TE in its original package to protect it from light.
    • Store the KOÄ€TE package at 2 to 8°C (36 to 46°F). Do not freeze.
    • KOÄ€TE may also be stored at room temperature (up to 25°C or 77°F) for up to 6 months.
    • Do not use after the expiration date.
    • Use reconstituted KOÄ€TE immediately or within 3 hours of reconstitution.

  • 17 PATIENT COUNSELING INFORMATION

    • Inform patients to immediately report the following early signs and symptoms of hypersensitivity reactions to their healthcare professional: angioedema, chest tightness, hypotension, rash, nausea, vomiting, paresthesia, restlessness, wheezing and dyspnea. [see Warnings and Precautions (5.1)]
    • Inform patients that the development of inhibitors to Factor VIII is a possible complication of treatment with KOÄ€TE. Advise the patients to contact their healthcare provider for further treatment and/or assessment if they experience a lack of clinical response to KOÄ€TE because this may be a manifestation of an inhibitor. [see Warnings and Precautions (5.2)]
    • Inform patients that KOÄ€TE is made from human plasma and may carry a risk of transmitting infectious agents. While the risk that KOÄ€TE can transmit an infection has been reduced by screening plasma donors for prior exposure, testing donated plasma, and inactivating or removing certain viruses during manufacturing, patients should report any symptoms that concern them. [see Warnings and Precautions (5.4)

    Manufactured for:
    Kedrion Biopharma Inc
    400 Kelby Street
    Fort Lee, NJ 07024

    Manufactured by:
    Grifols Therapeutics Inc.
    Research Triangle Park, NC 27709 USA
    US License No. 1871
    3036433


  • PACKAGE LABEL PRINCIPAL DISPLAY PANEL

    NDC 76125-252-21

    Koāte®

    Antihemophilic Factor (Human)

    Solvent/Detergent Treated

    Heat-Treated at 80°C

    Manufactured for:
    Kedrion Biopharma Inc.
    400 Kelby Street, Fort Lee, NJ 07024

    Manufactured by:
    Grifols Therapeutics Inc.
    Research Triangle Park, NC 27709 USA
    U.S. License No. 1871

    The patient and physician should discuss the risks and benefits of this product.

    No Preservative

    For Intravenous Administration Only

    Sterile—Nonpyrogenic

    Reconstitute with 5 mL Sterile Water for Injection, USP.

    Store at 2–8°C (36–46°F) and no more than 6 months at room temperature (up to 25°C; 77°F) at any time prior to the expiration date.

    Dosage and Administration: Read package insert.

    Rx only

    Date removed from refrigeration_____________________

    Lot

    Exp.

    IU

    3043909

    5 ml 250iu vial

    NDC 13533-000-04

    08941513

    Nonpyrogenic

    Single-Dose Container

    5 mL

    Sterile Water for Injection, USP
    for reconstitution of accompanying product

    Do not use unless clear. No antimicrobial agent or other substance has been added. Do not use for intravascular injection without making approximately isotonic by addition of suitable solute. Discard unused portion.

    Rx Only.

    Mfd by: Baxter Healthcare Corporation
                  Deerfield, IL 60015 USA

    Mfd for: Grifols Therapeutics Inc.
                   Research Triangle Park, NC 27709 USA

    07-32-68-181

    Lot
    Exp.

    5 ml water

    NDC 76125-250-20

    Koāte®
    Antihemophilic Factor (Human)

    250 IU FVIII Range

    Solvent/Detergent Treated

    Heat-Treated at 80°C

    5 mL

    Rx only

    CONTENTS:
    One bottle of Koāte
    5 mL Sterile Water for Injection, USP
    One sterile filter needle
    One sterile double-ended transfer needle
    One sterile administration set

    No Preservative

    For Intravenous Administration Only

    Sterile — Nonpyrogenic

    Date removed from refrigeration___________________

    WARNING: THIS PRODUCT IS PREPARED FROM LARGE POOLS OF HUMAN PLASMA WHICH MAY CARRY THE RISK OF TRANSMITTING INFECTIOUS AGENTS.

    The patient and physician should discuss the risks and benefits of this product.

    Dosage and Administration: Read enclosed package insert.

    Store refrigerated at 2 to 8°C (36 to 46°F) and no more than 6 months at room temperature (up to 25°C; 77°F) at any time prior to the expiration date. Avoid freezing.

    Reconstitute with 5 mL Sterile Water for Injection, USP.

    Administer within 3 hours after reconstitution.

    This product when reconstituted contains not more than (NMT) 1500 μg/mL polyethylene glycol (PEG), NMT 0.05 M glycine, NMT 25 μg/mL polysorbate 80, NMT 5 μg/g tri-n-butyl phosphate (TNBP), NMT 3 mM calcium, NMT 1 μg/mL aluminum, NMT 0.06 M histidine, and NMT 10 mg/mL Albumin (Human).

    If the shrink band is absent or shows any sign of tampering, do not use the product and notify Grifols Therapeutics Inc. immediately.

    Not Returnable for Credit or Exchange

    Manufactured for:
    Kedrion Biopharma Inc.
    400 Kelby Street, Fort Lee, NJ 07024

    Manufactured by:
    Grifols Therapeutics Inc.
    Research Triangle Park, NC 27709 USA

    U.S. License No. 1871

    Carton: 3041412

    5 ml 250iu carton-2

    NDC 76125-669-31

    Koāte®

    Antihemophilic Factor (Human)

    Solvent/Detergent Treated

    Heat-Treated at 80°C

    Manufactured for:
    Kedrion Biopharma Inc.
    400 Kelby Street, Fort Lee, NJ 07024

    Manufactured by:
    Grifols Therapeutics Inc.
    Research Triangle Park, NC 27709 USA
    U.S. License No. 1871

    The patient and physician should discuss the risks and benefits of this product.

    No Preservative

    For Intravenous Administration Only

    Sterile—Nonpyrogenic

    Reconstitute with 5 mL Sterile Water for Injection, USP.

    Store at 2–8°C (36–46°F) and no more than 6 months at room temperature (up to 25°C; 77°F) at any time prior to the expiration date.

    Dosage and Administration: Read package insert.

    Rx only

    Date removed from refrigeration_____________________

    Lot

    Exp.

    IU

    3043910

    5 ml 250iu vial

    NDC 76125-667-30

    Koāte®
    Antihemophilic Factor (Human)

    500 IU FVIII Range

    Solvent/Detergent Treated

    Heat-Treated at 80°C

    5 mL

    Rx only

    CONTENTS:
    One bottle of Koāte
    5 mL Sterile Water for Injection, USP
    One sterile filter needle
    One sterile double-ended transfer needle
    One sterile administration set

    No Preservative

    For Intravenous Administration Only

    Sterile — Nonpyrogenic

    Date removed from refrigeration___________________

    WARNING: THIS PRODUCT IS PREPARED FROM LARGE POOLS OF HUMAN PLASMA WHICH MAY CARRY THE RISK OF TRANSMITTING INFECTIOUS AGENTS.

    The patient and physician should discuss the risks and benefits of this product.

    Dosage and Administration: Read enclosed package insert.

    Store refrigerated at 2 to 8°C (36 to 46°F) and no more than 6 months at room temperature (up to 25°C; 77°F) at any time prior to the expiration date. Avoid freezing.

    Reconstitute with 5 mL Sterile Water for Injection, USP.

    Administer within 3 hours after reconstitution.

    This product when reconstituted contains not more than (NMT) 1500 μg/mL polyethylene glycol (PEG), NMT 0.05 M glycine, NMT 25 μg/mL polysorbate 80, NMT 5 μg/g tri-n-butyl phosphate (TNBP), NMT 3 mM calcium, NMT 1 μg/mL aluminum, NMT 0.06 M histidine, and NMT 10 mg/mL Albumin (Human).

    If the shrink band is absent or shows any sign of tampering, do not use the product and notify Grifols Therapeutics Inc. immediately.

    Not Returnable for Credit or Exchange

    Manufactured for:
    Kedrion Biopharma Inc.
    400 Kelby Street, Fort Lee, NJ 07024

    Manufactured by:
    Grifols Therapeutics Inc.
    Research Triangle Park, NC 27709 USA

    U.S. License No. 1871

    Carton: 3041413

    5 ml 500iu carton

    NDC 76125-673-51

    Koāte®

    Antihemophilic Factor (Human)

    Solvent/Detergent Treated

    Heat-Treated at 80°C

    Manufactured for:
    Kedrion Biopharma Inc.
    400 Kelby Street, Fort Lee, NJ 07024

    Manufactured by:
    Grifols Therapeutics Inc.
    Research Triangle Park, NC 27709 USA
    U.S. License No. 1871

    The patient and physician should discuss the risks and benefits of this product.

    No Preservative

    For Intravenous Administration Only

    Sterile—Nonpyrogenic

    Reconstitute with 10 mL Sterile Water for Injection, USP.

    Store at 2–8°C (36–46°F) and no more than 6 months at room temperature (up to 25°C; 77°F) at any time prior to the expiration date.

    Dosage and Administration: Read package insert.

    Rx only

    Date removed from refrigeration_____________________

    Lot

    Exp.

    IU

    3043911

    10 ml 1000 iu vial

    NDC 76125-672-50

    Koāte®
    Antihemophilic Factor (Human)

    1000 IU FVIII Range

    Solvent/Detergent Treated

    Heat-Treated at 80°C

    10 mL

    Rx only

    CONTENTS:
    One bottle of Koāte
    10 mL Sterile Water for Injection, USP
    One sterile filter needle
    One sterile double-ended transfer needle
    One sterile administration set

    No Preservative

    For Intravenous Administration Only

    Sterile — Nonpyrogenic

    Date removed from refrigeration___________________

    WARNING: THIS PRODUCT IS PREPARED FROM LARGE POOLS OF HUMAN PLASMA WHICH MAY CARRY THE RISK OF TRANSMITTING INFECTIOUS AGENTS.

    The patient and physician should discuss the risks and benefits of this product.

    Dosage and Administration: Read enclosed package insert.

    Store refrigerated at 2 to 8°C (36 to 46°F) and no more than 6 months at room temperature (up to 25°C; 77°F) at any time prior to the expiration date. Avoid freezing.

    Reconstitute with 10 mL Sterile Water for Injection, USP.

    Administer within 3 hours after reconstitution.

    This product when reconstituted contains not more than (NMT) 1500 μg/mL polyethylene glycol (PEG), NMT 0.05 M glycine, NMT 25 μg/mL polysorbate 80, NMT 5 μg/g tri-n-butyl phosphate (TNBP), NMT 3 mM calcium, NMT 1 μg/mL aluminum, NMT 0.06 M histidine, and NMT 10 mg/mL Albumin (Human).

    Not Returnable for Credit or Exchange

    Manufactured for:
    Kedrion Biopharma Inc.
    400 Kelby Street, Fort Lee, NJ 07024

    Manufactured by:
    Grifols Therapeutics Inc.
    Research Triangle Park, NC 27709 USA

    U.S. License No. 1871

    Carton: 3041414

    10 ml 1000 iu carton-2

    NDC 13533-000-05

    08941514

    Nonpyrogenic

    Single-Dose Container

    10 mL

    Sterile Water for Injection, USP
    for reconstitution of accompanying product

    Do not use unless clear. No antimicrobial agent or other substance has been added. Do not use for intravascular injection without making approximately isotonic by addition of suitable solute. Discard unused portion.

    Rx Only.

    Mfd by: Baxter Healthcare Corporation
                  Deerfield, IL 60015 USA

    Mfd for: Grifols Therapeutics Inc.
                   Research Triangle Park, NC 27709 USA

    07-32-68-183

    Lot
    Exp.

    10 ml water

  • INGREDIENTS AND APPEARANCE
    KOATE  
    antihemophilic factor (human) kit
    Product Information
    Product Type PLASMA DERIVATIVE Item Code (Source) NDC:76125-250
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:76125-250-20 1 in 1 CARTON; Type 9: Other Type of Part 3 Combination Product (e.g., Drug/Device/Biological Product)
    Quantity of Parts
    Part # Package Quantity Total Product Quantity
    Part 1 1 VIAL, GLASS 5 mL
    Part 2 1 VIAL, GLASS 5 mL
    Part 1 of 2
    KOATE  
    antihemophilic factor (human) injection, powder, lyophilized, for solution
    Product Information
    Item Code (Source) NDC:76125-252
    Route of Administration INTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    Antihemophilic Factor Human (UNII: 839MOZ74GK) (Antihemophilic Factor Human - UNII:839MOZ74GK) Antihemophilic Factor Human 250 [iU]  in 5 mL
    Inactive Ingredients
    Ingredient Name Strength
    Albumin Human (UNII: ZIF514RVZR)  
    Sodium Chloride (UNII: 451W47IQ8X)  
    Histidine (UNII: 4QD397987E)  
    Calcium Chloride (UNII: M4I0D6VV5M)  
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:76125-252-21 5 mL in 1 VIAL, GLASS; Type 0: Not a Combination Product
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    BLA BLA101130 05/20/1999
    Part 2 of 2
    STERILE WATER  
    water injection
    Product Information
    Item Code (Source) NDC:13533-000
    Route of Administration INTRAVENOUS
    Inactive Ingredients
    Ingredient Name Strength
    Water (UNII: 059QF0KO0R)  
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:13533-000-04 5 mL in 1 VIAL, GLASS; Type 0: Not a Combination Product
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    BLA BLA101130 05/20/1999
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    BLA BLA101130 05/20/1999
    KOATE  
    antihemophilic factor (human) kit
    Product Information
    Product Type PLASMA DERIVATIVE Item Code (Source) NDC:76125-253
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:76125-253-25 1 in 1 CARTON; Type 9: Other Type of Part 3 Combination Product (e.g., Drug/Device/Biological Product)
    Quantity of Parts
    Part # Package Quantity Total Product Quantity
    Part 1 1 VIAL, GLASS 5 mL
    Part 2 1 VIAL, GLASS 5 mL
    Part 1 of 2
    KOATE  
    antihemophilic factor (human) injection, powder, lyophilized, for solution
    Product Information
    Item Code (Source) NDC:76125-252
    Route of Administration INTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    Antihemophilic Factor Human (UNII: 839MOZ74GK) (Antihemophilic Factor Human - UNII:839MOZ74GK) Antihemophilic Factor Human 250 [iU]  in 5 mL
    Inactive Ingredients
    Ingredient Name Strength
    Albumin Human (UNII: ZIF514RVZR)  
    Sodium Chloride (UNII: 451W47IQ8X)  
    Histidine (UNII: 4QD397987E)  
    Calcium Chloride (UNII: M4I0D6VV5M)  
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:76125-252-21 5 mL in 1 VIAL, GLASS; Type 0: Not a Combination Product
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    BLA BLA101130 05/20/1999
    Part 2 of 2
    STERILE WATER  
    water injection
    Product Information
    Item Code (Source) NDC:13533-200
    Route of Administration INTRAVENOUS
    Inactive Ingredients
    Ingredient Name Strength
    Water (UNII: 059QF0KO0R)  
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:13533-200-05 5 mL in 1 VIAL, GLASS; Type 0: Not a Combination Product
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    BLA BLA101130 05/20/1999
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    BLA BLA101130 05/20/1999
    KOATE  
    antihemophilic factor (human) kit
    Product Information
    Product Type PLASMA DERIVATIVE Item Code (Source) NDC:76125-667
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:76125-667-30 1 in 1 CARTON; Type 9: Other Type of Part 3 Combination Product (e.g., Drug/Device/Biological Product)
    Quantity of Parts
    Part # Package Quantity Total Product Quantity
    Part 1 1 VIAL, GLASS 5 mL
    Part 2 1 VIAL, GLASS 5 mL
    Part 1 of 2
    KOATE  
    antihemophilic factor (human) injection, powder, lyophilized, for solution
    Product Information
    Item Code (Source) NDC:76125-669
    Route of Administration INTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    Antihemophilic Factor Human (UNII: 839MOZ74GK) (Antihemophilic Factor Human - UNII:839MOZ74GK) Antihemophilic Factor Human 500 [iU]  in 5 mL
    Inactive Ingredients
    Ingredient Name Strength
    Albumin Human (UNII: ZIF514RVZR)  
    Sodium Chloride (UNII: 451W47IQ8X)  
    Histidine (UNII: 4QD397987E)  
    Calcium Chloride (UNII: M4I0D6VV5M)  
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:76125-669-31 5 mL in 1 VIAL, GLASS; Type 0: Not a Combination Product
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    BLA BLA101130 05/20/1999
    Part 2 of 2
    STERILE WATER  
    water injection
    Product Information
    Item Code (Source) NDC:13533-000
    Route of Administration INTRAVENOUS
    Inactive Ingredients
    Ingredient Name Strength
    Water (UNII: 059QF0KO0R)  
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:13533-000-04 5 mL in 1 VIAL, GLASS; Type 0: Not a Combination Product
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    BLA BLA101130 05/20/1999
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    BLA BLA101130 05/20/1999
    KOATE  
    antihemophilic factor (human) kit
    Product Information
    Product Type PLASMA DERIVATIVE Item Code (Source) NDC:76125-662
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:76125-662-50 1 in 1 CARTON; Type 9: Other Type of Part 3 Combination Product (e.g., Drug/Device/Biological Product)
    Quantity of Parts
    Part # Package Quantity Total Product Quantity
    Part 1 1 VIAL, GLASS 5 mL
    Part 2 1 VIAL, GLASS 5 mL
    Part 1 of 2
    KOATE  
    antihemophilic factor (human) injection, powder, lyophilized, for solution
    Product Information
    Item Code (Source) NDC:76125-669
    Route of Administration INTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    Antihemophilic Factor Human (UNII: 839MOZ74GK) (Antihemophilic Factor Human - UNII:839MOZ74GK) Antihemophilic Factor Human 500 [iU]  in 5 mL
    Inactive Ingredients
    Ingredient Name Strength
    Albumin Human (UNII: ZIF514RVZR)  
    Sodium Chloride (UNII: 451W47IQ8X)  
    Histidine (UNII: 4QD397987E)  
    Calcium Chloride (UNII: M4I0D6VV5M)  
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:76125-669-31 5 mL in 1 VIAL, GLASS; Type 0: Not a Combination Product
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    BLA BLA101130 05/20/1999
    Part 2 of 2
    STERILE WATER  
    water injection
    Product Information
    Item Code (Source) NDC:13533-200
    Route of Administration INTRAVENOUS
    Inactive Ingredients
    Ingredient Name Strength
    Water (UNII: 059QF0KO0R)  
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:13533-200-05 5 mL in 1 VIAL, GLASS; Type 0: Not a Combination Product
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    BLA BLA101130 05/20/1999
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    BLA BLA101130 05/20/1999
    KOATE  
    antihemophilic factor (human) kit
    Product Information
    Product Type PLASMA DERIVATIVE Item Code (Source) NDC:76125-672
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:76125-672-50 1 in 1 CARTON; Type 9: Other Type of Part 3 Combination Product (e.g., Drug/Device/Biological Product)
    Quantity of Parts
    Part # Package Quantity Total Product Quantity
    Part 1 1 VIAL, GLASS 10 mL
    Part 2 1 VIAL, GLASS 10 mL
    Part 1 of 2
    KOATE  
    antihemophilic factor (human) injection, powder, lyophilized, for solution
    Product Information
    Item Code (Source) NDC:76125-673
    Route of Administration INTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    Antihemophilic Factor Human (UNII: 839MOZ74GK) (Antihemophilic Factor Human - UNII:839MOZ74GK) Antihemophilic Factor Human 1000 [iU]  in 10 mL
    Inactive Ingredients
    Ingredient Name Strength
    Albumin Human (UNII: ZIF514RVZR)  
    Sodium Chloride (UNII: 451W47IQ8X)  
    Histidine (UNII: 4QD397987E)  
    Calcium Chloride (UNII: M4I0D6VV5M)  
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:76125-673-51 10 mL in 1 VIAL, GLASS; Type 0: Not a Combination Product
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    BLA BLA101130 05/20/1999
    Part 2 of 2
    STERILE WATER  
    water injection
    Product Information
    Item Code (Source) NDC:13533-000
    Route of Administration INTRAVENOUS
    Inactive Ingredients
    Ingredient Name Strength
    Water (UNII: 059QF0KO0R)  
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:13533-000-05 10 mL in 1 VIAL, GLASS; Type 0: Not a Combination Product
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    BLA BLA101130 05/20/1999
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    BLA BLA101130 05/20/1999
    KOATE  
    antihemophilic factor (human) kit
    Product Information
    Product Type PLASMA DERIVATIVE Item Code (Source) NDC:76125-674
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:76125-674-10 1 in 1 CARTON; Type 9: Other Type of Part 3 Combination Product (e.g., Drug/Device/Biological Product)
    Quantity of Parts
    Part # Package Quantity Total Product Quantity
    Part 1 1 VIAL, GLASS 10 mL
    Part 2 1 VIAL, GLASS 10 mL
    Part 1 of 2
    KOATE  
    antihemophilic factor (human) injection, powder, lyophilized, for solution
    Product Information
    Item Code (Source) NDC:76125-673
    Route of Administration INTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    Antihemophilic Factor Human (UNII: 839MOZ74GK) (Antihemophilic Factor Human - UNII:839MOZ74GK) Antihemophilic Factor Human 1000 [iU]  in 10 mL
    Inactive Ingredients
    Ingredient Name Strength
    Albumin Human (UNII: ZIF514RVZR)  
    Sodium Chloride (UNII: 451W47IQ8X)  
    Histidine (UNII: 4QD397987E)  
    Calcium Chloride (UNII: M4I0D6VV5M)  
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:76125-673-51 10 mL in 1 VIAL, GLASS; Type 0: Not a Combination Product
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    BLA BLA101130 05/20/1999
    Part 2 of 2
    STERILE WATER  
    water injection
    Product Information
    Item Code (Source) NDC:13533-200
    Route of Administration INTRAVENOUS
    Inactive Ingredients
    Ingredient Name Strength
    Water (UNII: 059QF0KO0R)  
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:13533-200-10 10 mL in 1 VIAL, GLASS; Type 0: Not a Combination Product
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    BLA BLA101130 05/20/1999
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    BLA BLA101130 05/20/1999
    Labeler - KEDRION BIOPHARMA, INC. (078622209)
    Establishment
    Name Address ID/FEI Business Operations
    Grifols Therapeutics Inc. 611019113 manufacture(76125-250, 76125-253, 76125-662, 76125-667, 76125-672, 76125-674)